FactorIX抗体;FactorIX Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Factor IX expression in human plasma lysate.    

  
  

Factor IX antibodies, also called inhibitors, are neutralizing alloantibodies that target coagulation Factor IX, a vitamin K-dependent serine protease critical for blood clotting. These antibodies primarily arise in individuals with hemophilia B (congenital Factor IX deficiency) as an immune response to replacement therapy. Following exogenous Factor IX administration, approximately 1.5-3% of hemophilia B patients develop inhibitors, typically IgG-type antibodies that bind to Factor IX’s catalytic domain or Gla domain, impairing its procoagulant function. Inhibitor development correlates with severe genetic mutations (e.g., large F9 gene deletions) and presents clinical challenges by rendering standard replacement therapy ineffective.

Therapeutic management involves immune tolerance induction (ITI) protocols using high-dose Factor IX concentrates, though success rates remain lower than in hemophilia A. Bypassing agents like recombinant Factor VIIa or activated prothrombin complex concentrates (FEIBA) are used for acute bleeding. Notably, anaphylactic reactions may occur in ~25% of pediatric patients with inhibitors during initial Factor IX exposures.

Beyond hemophilia B, acquired Factor IX autoantibodies (spontaneous inhibitors) are rare but associated with autoimmune disorders, pregnancy, or malignancy. Laboratory diagnosis combines functional assays (e.g., Bethesda assay) to quantify inhibitor titers and immunological tests to confirm antibody specificity. Research efforts focus on novel therapies, including bispecific antibodies (e.g., emicizumab) and gene therapy approaches to reduce immunogenicity and improve outcomes. Monitoring antibody titers remains essential for personalized treatment strategies.